Bio-Path Holdings, Inc. Appoints Paul Aubert to Its Board of Directors
February 05, 2018 at 06:30 pm IST
Share
Bio-Path Holdings, Inc. announced the appointment of Paul Aubert to its Board of Directors. Mr. Aubert is currently the sole Shareholder at Paul Aubert PLLC. Earlier, he was a Shareholder at Winstead PC. Mr. Aubert has also worked as an attorney in the Corporate and Securities practice groups at several other national and international law firms.
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
BIO-PATH HOLDINGS, INC. 
